180 related articles for article (PubMed ID: 19033694)
1. Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
[TBL] [Abstract][Full Text] [Related]
2. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
Maeda LS; Advani RH
Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
[TBL] [Abstract][Full Text] [Related]
3. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
Younes A; Romaguera J; Hagemeister F; McLaughlin P; Rodriguez MA; Fiumara P; Goy A; Jeha S; Manning JT; Jones D; Abruzzo LV; Medeiros LJ
Cancer; 2003 Jul; 98(2):310-4. PubMed ID: 12872350
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU; Choquet S; Reinke P; Dreyling M; Mergenthaler HG; Jäger U; Kebelmann-Betzing C; Jonas S; Lehmkuhl H; Anagnostopoulos I; Leblond V; Hetzer R; Dörken B; Riess H; Oertel S
Transplantation; 2007 Dec; 84(12):1708-12. PubMed ID: 18165786
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
[TBL] [Abstract][Full Text] [Related]
8. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
Chera BS; Olivier K; Morris CG; Lynch JW; Mendenhall NP
Am J Clin Oncol; 2007 Dec; 30(6):601-6. PubMed ID: 18091054
[TBL] [Abstract][Full Text] [Related]
10. Case of relapsed CD20(+) mixed-cellularity Hodgkin disease treated with sequential rituximab and radiotherapy.
Karamouzis MV; Apostolikas N; Georganta C; Lainakis G; Kandylis K; Rigatos G
Am J Hematol; 2004 Dec; 77(4):418-9. PubMed ID: 15551291
[No Abstract] [Full Text] [Related]
11. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
Ibom VK; Prosnitz RG; Gong JZ; Moore JO; DeCastro CM; Prosnitz LR; Rizzieri DA; Gockerman JP
Clin Lymphoma; 2003 Sep; 4(2):115-8. PubMed ID: 14556684
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
14. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
15. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
[TBL] [Abstract][Full Text] [Related]
16. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-predominant Hodgkin's lymphoma.
Horwich A; Cunningham D
J Clin Oncol; 2010 Jul; 28(19):e325; author reply e326. PubMed ID: 20516449
[No Abstract] [Full Text] [Related]
19. Developing anticancer chemotherapy services in a developing country: Hodgkin lymphoma experience.
Chandra J; Naithani R; Singh V; Saxena YK; Sharma M; Pemde H
Pediatr Blood Cancer; 2008 Oct; 51(4):485-8. PubMed ID: 18636462
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience.
Biswas G; Parikh PM; Nair R; Bhagwat R; Bakshi A; Prabhash K; Vora A; Gupta S; Pai VR; Menon H; Sastry PS
J Assoc Physicians India; 2006 Jan; 54():29-33. PubMed ID: 16649735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
